Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2017 / Cilt: 70 - Sayı: 1

Chromosomal Anomalies in Acute Myeloid Leukemia: Cytogenetic Results of -417 Cases Froma Single Center

Akut Miyeloid Lösemide Kromozomal Anomaliler: Tek Merkezden 417 Olgunun Sitogenetik Sonuçları

Pages
37–51
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There are genes known to be associated or potentially associated with hematopoietic or lymphoid tissue malignancies in some of the break points detected, yet there are no defined genes for some.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Cytogenetic markers have important roles in the diagnosis and follow up of leukemia patients.
📊
Key Findings & Data:Over 150 recurrent numerical and structural chromosomal changes have been reported in AML.
💡
Conclusion & Impact:There are genes known to be associated or potentially associated with hematopoietic or lymphoid tissue malignancies in some of the break points detected, yet there are no defined genes for some.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Cytogenetic markers have important roles in the diagnosis and follow up of leukemia patients. In AML patients cytogenetic results are relatively more complicated compared to other leukemias. Over 150 recurrent numerical and structural chromosomal changes have been reported in AML. Evaluation of cytogenetic analysis results of large patient series will help the genetic knowledge about AML formation to accumulate and also to define novel prognostic or diagnostic markers. Material and Method: In this study, cytogenetic analysis results obtained in accordance with standard cell culture protocol of peripheral blood or bone marrow samples of 417 patients diagnosed with AML archived in the Ankara University Medicine Faculty, Center for Genetic Diseases and Diagnosis were evaluated retrospectively. Results: After a detailed review of this series, a novel deletion and 13 different chromosomal rearrangements were shown for the first time along with known numerical and structural alterations for AML like t(15;17), t(16;16), t(8;21), del(11)(q), monosomy 7 and trisomy 8. Conclusion: In this paper, distribution of defined numerical and structural rearrangements and possible association of novel cytogenetic alterations with AML development were discussed. The break points we detected have been previously reported in different rearrangements of various malignancies. However, the arrangements detected in our series are with different combinations and lead to novel gene fusions. There are genes known to be associated or potentially associated with hematopoietic or lymphoid tissue malignancies in some of the break points detected, yet there are no defined genes for some.

Özet

Amaç: Lösemi hastalarının tanısında ve izleminde sitogenetik belirteçlerin önemli rolü vardır. Lösemiler içinde akut miyelositer lösemi (AML) hastalarında, sitogenetik sonuçlar göreceli olarak daha karmasıktır. AML hastalarında 150'den fazla, yapısal ve sayısal, tekrarlayan kromozomal değisiklik bildirilmistir. Genis hasta serilerinin sitogenetik analiz sonuçlarının değerlendirilmesi, AML gelisimi konusundaki genetik bilgilerin artmasını, prognostik ya da diagnostik yeni belirteçler bulunmasını sağlayacaktır. Gereç ve yöntem: Bu çalısmada Ankara Üniversitesi Tıp Fakültesi Genetik Hastalıklar Tanı Merkezinde arsivlenen, AML tanılı 417 hastanın periferik kan/kemik iliği örneklerinden standart protokole uygun olarak yapılan hücre kültürlerinden elde edilen sitogenetik analiz sonuçları retrospektif olarak değerlendirilmistir. Bulgular: Bu serinin incelenmesi sonucunda, AML için bilinen; t(15;17), t(16;16), t(8;21), del11q, monozomi 7 ve trizomi 8 gibi yapısal ve sayısal değisikliklerin yanı sıra yeni bir delesyon ve 13 farklı kromozomal yeniden düzenlenme ilk olarak gösterilmistir. Sonuç: Çalısmamızda tanımlı sayısal ve yapısal değisikliklerin dağılımı ile yeni bulunan kromozomal düzenlenmelerin AML gelisimi üzerine olabilecek etkileri tartısılmıstır. Saptadığımız kırık noktaları çesitli malignitelerde tanımlanan farklı yeni düzenlenmelerde daha önce raporlanmıstır. Ancak bu seride belirlenen değisikliklerde, farklı kombinasyonlar ve buna bağlı olarak önceden saptanmamıs gen füzyonlarının olustuğu görülmektedir. Belirlenen kırık noktalarından bazılarında hematopoetik veya lenfoid doku maligniteleri ile iliskilendirilmis ya da olası iliskili tanımlı genler bulunurken, bazılarında henüz bir gen tanımlanmamıstır.

🔖

Cite This Article

YÜRÜRKUTLAY, N. (2022). Chromosomal Anomalies in Acute Myeloid Leukemia: Cytogenetic Results of -417 Cases Froma Single Center. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 70 - Sayı: 1, 37–51. https://ajindex.com/articles/443678

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 2016;6:e441. doi: 10.1038/bcj.2016.50 2. Kansal R. Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer Biol Med 2016;13: 41-54. doi: 10.28092/j.issn.2095- 3941.2016.0001. 3. Atlas of Genetics and Cytogenetics in Oncology and Haematology. http://atlasgeneticsoncology.org/ 4. National Cancer Instıtute. Cancer Genome Anatomy Project. Mitelman Database ofChromosome Aberations and Gene Fusions in Cancer. https://cgap.nci.nih.gov/Chromosomes/ AbnCytSearchForm 5. Czepulkowski B. Basic techniques for the preparation and analysis of chromosomesfrom bone marrowandleukemicblood. In: Rooney DE Ed. Human Cytogenetics Malignancy and Acquired Abnormalities. 3rd ed. Oxford: Oxford University Press, 2001. p:1-26. 6. Specchia G, Albano F, Anelli L, etal. Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. Genes ChromosomesCancer. 2004;41(1):86-91. 7. Ogawa S, Yokoyama Y, Suzukawa K, etal. Identification of a fusion gene composed of a Hippo pathway gene MST2 and a common translocation partner ETV6 in a recurrent translocation t(8;12) (q22;p13) in acute myeloid leukemia. Ann Hematol. 2015; 94(8): 1431-3. doi: 10.1007/s00277- 015-2391-2. Epub 2015 May 3. 8. Meyer C, Hofmann J, Burmeister T, et al.The MLL recombinome of acute leukemias in 2013.Leukemia 2013; 27(11): 2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30 9. Chapiro E, Russell L, Radford-Weiss I,et al. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblasticleukemia. Blood 2006;108: 3560-3. Epub 2006 Jul 27. 10. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells Clin Cancer Res. 2005;11:1372-9PMID 15746035 11. Bene MC, Castoldi G, Knapp W, et al. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 2004;18: 394-400. (REVIEW) PMID 14671631 12. Brambillasca F, Mosna G, Colombo M, et al. Identification of a novel molecular partner of the E2A gene in childhood leukemia. Leukemia 1999;13: 369-75. 13.Akasaka T, Lossos IS, Levy R.BCL6 gene translocation in follicular lymphoma: a harbing